The pursuit of new frontiers
towards p53
replacement therapy
AnserBio is building the future of oncology biotherapy
We are committed to transforming cancer care through our unique, patented therapeutic approach, which restores the key anti-cancer defense mechanism by leveraging the p53 tumor suppressor protein.
p53 plays a central role in natural anti-cancer defense
AnserBio has pioneered a groundbreaking method for delivering exogenous p53 protein using proprietary cell-derived nanoparticles.
​
We are transforming an ancient evolutionary defense mechanism into a cutting-edge systemic therapy.
Millions of lives are affected by cancer
new cancer cases annually worldwide
of human cancers are associated with mutation in gene TP53
widely approved
p53 therapies
Mission
AnserBio’s mission is to introduce a transformative therapy that restores the pinnacle of tumor suppression, through the p53 mechanism, using a safe, effective and unique therapeutic approach. We aim to impact the millions of lives affected by cancer
The science behind p53 and CDV​
Every healthy cell has a built-in DNA repair system, with the p53 protein acting as the "guardian of the genome" to fix mutations or trigger cell death (apoptosis) to prevent cancer. When the p53 gene itself is mutated, this protective mechanism is lost, increasing the risk of cancer or leading to a more aggressive spread of existing disease.
​
The high prevalence of p53 mutations in cancer highlights the potential impact of therapies that restore functional p53. At AnserBio, we deliver functional p53 via cell-derived nanovesicles, specifically exosomes --tiny extracellular vesicles that carry proteins, RNA, lipids, and metabolites - which are crucial for regulating cancer processes like angiogenesis, modulation of the immune system, and metastasis.
​
Our CSO, Yegveny Tendler, discovered the secretion of p53-containing exosomes. Leveraging this finding, AnserBio has developed proprietary cell-derived vesicles (CDVs). This innovation enhances yield and scalability, positioning AnserBio at the forefront of the exosome-based therapeutics field.
AnserBio is targeting oncology indications of high unmet need
Several challenging tumor types, including colon cancer, bladder cancer, ovarian cancer, and glioblastoma, are characterized by a high frequency of p53 mutations.
​
These cancers are highly aggressive and often resistant to existing therapies.
​
Despite billions of dollars invested annually in research, there is currently no widely approved therapy specifically targeting p53 mutant cancers.
​
Traditional treatments, such as chemotherapy and radiotherapy, often have significant side effects that compromise patient outcomes and quality of life.
We believe that introduction of our therapy will significantly enhance therapeutic options for patients.
PASSIONATE TEAM lead by A POWERFUL TANDEM
Dr. Lana Volokh and Dr. Alex Tendler have been working together since 2014
Co-founders since 2017
Describe your image